Parallel Development of Novel Vaccine Vectors (pilot study)

  • 42 pages

  • Published: 16 Sep 2014

  • Author(s): Devlin, Joanne

Share this content
  • twitter
  • facebook
  • email
  • Download report PDF

  • Purchase a hard copy - AUD $45.00

The report describes the results from a pilot study examining the use of an attenuated strain of infectious laryngotracheitis virus (ILTV, gallid herpesvirus 1) as a vector to express antigen from infectious bronchitis virus (IBV). This work was undertaken to assess the feasibility of using this attenuated ILTV strain as a vaccine vector.